Peter Farrell Sells 970 Shares of ResMed (NYSE:RMD) Stock

Posted by Brian Himes on Sep 6th, 2026

ResMed Inc. (NYSE:RMD – Get Free Report) Director Peter Farrell sold 970 shares of ResMed stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $234.73, for a total value of $227,688.10. Following the sale, the director owned 51,803 shares in the company, valued at $12,159,718.19. This represents a 1.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ResMed Price Performance

Shares of NYSE RMD opened at $228.25 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.42 and a current ratio of 3.10. The company has a market capitalization of $32.93 billion, a price-to-earnings ratio of 21.88, a P/E/G ratio of 1.43 and a beta of 0.77. ResMed Inc. has a fifty-two week low of $180.26 and a fifty-two week high of $284.87. The company has a 50 day simple moving average of $215.51 and a two-hundred day simple moving average of $218.22.

ResMed (NYSE:RMD – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $2.95 EPS for the quarter, beating analysts’ consensus estimates of $2.89 by $0.06. ResMed had a net margin of 26.94% and a return on equity of 25.58%. The firm had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.46 billion. During the same quarter in the prior year, the company posted $2.55 earnings per share. The business’s revenue for the quarter was up 8.6% on a year-over-year basis. Analysts expect that ResMed Inc. will post 12.02 EPS for the current fiscal year.

ResMed Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 24th. Investors of record on Thursday, August 20th will be given a dividend of $0.66 per share. This represents a $2.64 dividend on an annualized basis and a yield of 1.2%. This is a boost from ResMed’s previous quarterly dividend of $0.60. The ex-dividend date is Thursday, August 20th. ResMed’s dividend payout ratio (DPR) is currently 25.31%.

Analysts Set New Price Targets

RMD has been the subject of a number of research reports. Rothschild & Co Redburn began coverage on shares of ResMed in a report on Wednesday, August 19th. They set a “neutral” rating and a $230.00 target price for the company. Wells Fargo & Company decreased their target price on ResMed from $225.00 to $215.00 and set an “equal weight” rating on the stock in a report on Friday, August 7th. Piper Sandler lowered their target price on ResMed from $233.00 to $225.00 and set a “neutral” rating on the stock in a research report on Friday, August 7th. Citigroup reissued a “neutral” rating and set a $235.00 price target (down from $270.00) on shares of ResMed in a report on Sunday, July 12th. Finally, Mizuho reduced their price target on ResMed from $235.00 to $220.00 and set an “outperform” rating for the company in a research report on Wednesday, July 15th. Six investment analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, ResMed has a consensus rating of “Hold” and a consensus target price of $240.31.

View Our Latest Stock Analysis on RMD

Institutional Investors Weigh In On ResMed

A number of hedge funds have recently made changes to their positions in the company. American Capital Management Inc. purchased a new position in ResMed in the second quarter worth about $44,522,000. Hsbc Holdings PLC increased its stake in ResMed by 17.6% during the fourth quarter. Hsbc Holdings PLC now owns 328,785 shares of the medical equipment provider’s stock worth $79,321,000 after acquiring an additional 49,253 shares during the last quarter. BlackRock Inc. purchased a new stake in ResMed during the second quarter valued at approximately $2,400,375,000. Goldman Sachs Group Inc. raised its position in ResMed by 13.7% during the fourth quarter. Goldman Sachs Group Inc. now owns 979,087 shares of the medical equipment provider’s stock valued at $235,833,000 after purchasing an additional 118,296 shares during the period. Finally, Polymer Capital Management HK LTD bought a new stake in shares of ResMed in the 2nd quarter valued at approximately $972,000. 54.98% of the stock is currently owned by hedge funds and other institutional investors.

ResMed Company Profile

(Get Free Report)

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.